Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer

Tobias Klatte, Evanguelos Xylinas, Malte Rieken, Luis A. Kluth, Morgan Rouprêt, Armin Pycha, Harun Fajkovic, Christian Seitz, Pierre I. Karakiewicz, Yair Lotan, Marko Babjuk, Michela De Martino, Douglas S. Scherr, Shahrokh F. Shariat

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Purpose ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma. Materials and Methods We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index. Results The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type O had worse recurrence and progression rates than those with A (p = 0.015 and 0.031) or B (p = 0.004 and 0.075, respectively). The concordance index of multivariable base models increased after including ABO blood type. Conclusions In patients with nonmuscle invasive bladder urothelial carcinoma the ABO blood type may predict the outcome. Those with blood type O showed the highest recurrence and progression rates. Including ABO blood type in multivariable models increases the accuracy of standard prognostic factors. Since the ABO blood type is available for most patients, it may represent an ideal adjunctive marker to predict recurrence and progression. The biological explanation and prognostic value of this finding must be further elucidated.

Original languageEnglish (US)
Pages (from-to)1238-1243
Number of pages6
JournalJournal of Urology
Volume191
Issue number5
DOIs
StatePublished - May 2014

    Fingerprint

Keywords

  • ABO blood-group system
  • carcinoma
  • disease progression
  • local
  • neoplasm recurrence
  • urinary bladder

ASJC Scopus subject areas

  • Urology

Cite this

Klatte, T., Xylinas, E., Rieken, M., Kluth, L. A., Rouprêt, M., Pycha, A., Fajkovic, H., Seitz, C., Karakiewicz, P. I., Lotan, Y., Babjuk, M., De Martino, M., Scherr, D. S., & Shariat, S. F. (2014). Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. Journal of Urology, 191(5), 1238-1243. https://doi.org/10.1016/j.juro.2013.11.106